Richard Vandivier
Concepts (442)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 21 | 2025 | 919 | 3.140 |
Why?
| | Apoptosis | 23 | 2014 | 2440 | 2.080 |
Why?
| | Phagocytosis | 15 | 2014 | 296 | 1.910 |
Why?
| | Macrophages, Alveolar | 14 | 2019 | 373 | 1.140 |
Why?
| | Tobacco Smoke Pollution | 3 | 2022 | 227 | 1.100 |
Why?
| | Tissue Plasminogen Activator | 2 | 2018 | 248 | 0.970 |
Why?
| | Pulmonary Embolism | 2 | 2018 | 241 | 0.940 |
Why?
| | Respiratory Insufficiency | 4 | 2024 | 326 | 0.850 |
Why?
| | Smoking | 5 | 2018 | 1472 | 0.690 |
Why?
| | Lung | 13 | 2025 | 4106 | 0.690 |
Why?
| | Adrenal Cortex Hormones | 2 | 2015 | 484 | 0.670 |
Why?
| | Cigarette Smoking | 2 | 2025 | 102 | 0.650 |
Why?
| | rhoA GTP-Binding Protein | 6 | 2014 | 76 | 0.610 |
Why?
| | Pulmonary Ventilation | 2 | 2018 | 82 | 0.580 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2022 | 390 | 0.530 |
Why?
| | Pneumonia | 6 | 2023 | 636 | 0.520 |
Why?
| | Intensive Care Units | 7 | 2025 | 924 | 0.510 |
Why?
| | Delivery of Health Care, Integrated | 2 | 2011 | 303 | 0.500 |
Why?
| | Fibrinolytic Agents | 1 | 2018 | 297 | 0.460 |
Why?
| | rac1 GTP-Binding Protein | 3 | 2012 | 56 | 0.430 |
Why?
| | Pulmonary Alveoli | 4 | 2016 | 385 | 0.420 |
Why?
| | Stem Cells | 2 | 2018 | 628 | 0.420 |
Why?
| | Methylprednisolone | 1 | 2014 | 59 | 0.410 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 1 | 2014 | 62 | 0.400 |
Why?
| | Asthma | 3 | 2022 | 1797 | 0.400 |
Why?
| | Critical Illness | 8 | 2020 | 900 | 0.390 |
Why?
| | Patient Admission | 2 | 2025 | 220 | 0.390 |
Why?
| | Pulmonary Surfactant-Associated Protein D | 5 | 2016 | 31 | 0.390 |
Why?
| | Hospital Mortality | 6 | 2025 | 1038 | 0.380 |
Why?
| | Bronchiectasis | 2 | 2006 | 115 | 0.380 |
Why?
| | Hypnotics and Sedatives | 2 | 2025 | 222 | 0.370 |
Why?
| | Case Management | 1 | 2012 | 68 | 0.360 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2016 | 552 | 0.360 |
Why?
| | Alcoholism | 5 | 2023 | 822 | 0.360 |
Why?
| | Coronary Disease | 1 | 2015 | 381 | 0.360 |
Why?
| | Hospitalization | 6 | 2025 | 2460 | 0.360 |
Why?
| | Humans | 68 | 2025 | 145474 | 0.360 |
Why?
| | rho GTP-Binding Proteins | 2 | 2010 | 56 | 0.360 |
Why?
| | Serotonin | 1 | 2014 | 297 | 0.350 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 74 | 0.340 |
Why?
| | Noninvasive Ventilation | 2 | 2024 | 62 | 0.340 |
Why?
| | Cystic Fibrosis | 4 | 2006 | 1161 | 0.320 |
Why?
| | Pulmonary Surfactant-Associated Protein A | 3 | 2008 | 30 | 0.310 |
Why?
| | Patient Education as Topic | 2 | 2012 | 777 | 0.300 |
Why?
| | Inflammation Mediators | 4 | 2016 | 506 | 0.290 |
Why?
| | Neutrophils | 7 | 2010 | 1124 | 0.290 |
Why?
| | Mice | 21 | 2017 | 18329 | 0.280 |
Why?
| | Male | 39 | 2025 | 72842 | 0.280 |
Why?
| | Jurkat Cells | 6 | 2012 | 115 | 0.280 |
Why?
| | Interleukin-8 | 1 | 2009 | 269 | 0.270 |
Why?
| | Female | 37 | 2025 | 78844 | 0.260 |
Why?
| | Low Density Lipoprotein Receptor-Related Protein-1 | 3 | 2006 | 12 | 0.260 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2018 | 2028 | 0.260 |
Why?
| | Signal Transduction | 6 | 2014 | 5216 | 0.260 |
Why?
| | Cells, Cultured | 9 | 2016 | 4148 | 0.260 |
Why?
| | Middle Aged | 24 | 2025 | 36215 | 0.260 |
Why?
| | Benzodiazepines | 2 | 2025 | 168 | 0.250 |
Why?
| | Animals | 30 | 2017 | 38030 | 0.250 |
Why?
| | Acyl Coenzyme A | 1 | 2006 | 32 | 0.240 |
Why?
| | Intracellular Fluid | 1 | 2006 | 25 | 0.240 |
Why?
| | rho-Associated Kinases | 3 | 2014 | 82 | 0.240 |
Why?
| | Lovastatin | 1 | 2006 | 37 | 0.240 |
Why?
| | Lung Diseases, Obstructive | 1 | 2006 | 43 | 0.240 |
Why?
| | Collectins | 1 | 2006 | 6 | 0.240 |
Why?
| | Opsonin Proteins | 1 | 2006 | 19 | 0.230 |
Why?
| | Inflammation | 9 | 2016 | 2878 | 0.230 |
Why?
| | Retrospective Studies | 14 | 2025 | 17291 | 0.230 |
Why?
| | Substance-Related Disorders | 2 | 2025 | 1102 | 0.230 |
Why?
| | Chemotaxis, Leukocyte | 1 | 2006 | 114 | 0.230 |
Why?
| | Self Care | 1 | 2009 | 390 | 0.230 |
Why?
| | Quality of Life | 3 | 2022 | 3204 | 0.230 |
Why?
| | Ethanol | 1 | 2010 | 631 | 0.220 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2009 | 371 | 0.220 |
Why?
| | Leukocyte Elastase | 2 | 2002 | 75 | 0.220 |
Why?
| | Neuromuscular Blockade | 1 | 2025 | 53 | 0.220 |
Why?
| | Mice, Knockout | 8 | 2014 | 3124 | 0.220 |
Why?
| | Propofol | 1 | 2025 | 85 | 0.210 |
Why?
| | Oligopeptides | 1 | 2006 | 267 | 0.200 |
Why?
| | Influenza A virus | 1 | 2025 | 119 | 0.200 |
Why?
| | Mice, Inbred C57BL | 11 | 2014 | 5983 | 0.200 |
Why?
| | Shock, Septic | 2 | 2022 | 227 | 0.200 |
Why?
| | Cohort Studies | 6 | 2022 | 6013 | 0.200 |
Why?
| | Complement C1q | 2 | 2006 | 32 | 0.200 |
Why?
| | Aged | 17 | 2025 | 26153 | 0.200 |
Why?
| | Ibuprofen | 4 | 2001 | 87 | 0.200 |
Why?
| | Disease Progression | 4 | 2020 | 2864 | 0.200 |
Why?
| | Lipopolysaccharides | 5 | 2016 | 858 | 0.190 |
Why?
| | Respiratory System | 2 | 2018 | 150 | 0.190 |
Why?
| | Erythropoietin | 1 | 2004 | 100 | 0.190 |
Why?
| | Intracellular Signaling Peptides and Proteins | 2 | 2025 | 456 | 0.190 |
Why?
| | Calreticulin | 1 | 2002 | 22 | 0.190 |
Why?
| | Adult | 22 | 2025 | 40777 | 0.180 |
Why?
| | Extracellular Matrix | 1 | 2006 | 562 | 0.170 |
Why?
| | Patient Discharge | 2 | 2018 | 992 | 0.170 |
Why?
| | Smoke-Free Policy | 1 | 2021 | 13 | 0.160 |
Why?
| | Transforming Growth Factor beta | 4 | 2013 | 474 | 0.160 |
Why?
| | Treatment Outcome | 5 | 2022 | 11772 | 0.160 |
Why?
| | Smokers | 2 | 2019 | 138 | 0.160 |
Why?
| | Macrophages | 5 | 2010 | 1507 | 0.160 |
Why?
| | Tumor Necrosis Factor-alpha | 6 | 2009 | 1217 | 0.160 |
Why?
| | Mice, Inbred ICR | 3 | 2013 | 113 | 0.160 |
Why?
| | Endotoxins | 5 | 2013 | 217 | 0.150 |
Why?
| | Receptors, Cell Surface | 1 | 2002 | 372 | 0.150 |
Why?
| | Autoimmune Diseases | 2 | 2014 | 468 | 0.150 |
Why?
| | Analgesics, Opioid | 2 | 2025 | 1149 | 0.150 |
Why?
| | Granulomatous Disease, Chronic | 2 | 2010 | 49 | 0.150 |
Why?
| | Nitroprusside | 1 | 1999 | 71 | 0.150 |
Why?
| | Speech Therapy | 1 | 2019 | 21 | 0.150 |
Why?
| | Hexosaminidases | 1 | 2019 | 17 | 0.140 |
Why?
| | Influenza, Human | 1 | 2025 | 624 | 0.140 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 2018 | 37 | 0.140 |
Why?
| | Macrolides | 1 | 2019 | 67 | 0.140 |
Why?
| | Pharmacoepidemiology | 2 | 2019 | 23 | 0.140 |
Why?
| | Vecuronium Bromide | 1 | 2018 | 8 | 0.140 |
Why?
| | Atracurium | 1 | 2018 | 14 | 0.140 |
Why?
| | Heart Failure, Diastolic | 1 | 2018 | 23 | 0.140 |
Why?
| | Heart Failure, Systolic | 1 | 2018 | 26 | 0.130 |
Why?
| | Coronary Circulation | 1 | 2018 | 134 | 0.130 |
Why?
| | Bronchoalveolar Lavage Fluid | 5 | 2016 | 638 | 0.130 |
Why?
| | Neuromuscular Blocking Agents | 1 | 2018 | 28 | 0.130 |
Why?
| | Cardiologists | 1 | 2018 | 45 | 0.130 |
Why?
| | Time | 1 | 2018 | 84 | 0.130 |
Why?
| | Intubation, Intratracheal | 1 | 2020 | 325 | 0.130 |
Why?
| | Counseling | 1 | 2021 | 400 | 0.130 |
Why?
| | Polyneuropathies | 1 | 2017 | 57 | 0.130 |
Why?
| | Occupational Therapy | 1 | 2019 | 109 | 0.130 |
Why?
| | Up-Regulation | 2 | 2019 | 847 | 0.130 |
Why?
| | Epithelium | 1 | 2018 | 310 | 0.130 |
Why?
| | Nitric Oxide | 3 | 2006 | 892 | 0.120 |
Why?
| | Hypertension, Pulmonary | 4 | 2016 | 1957 | 0.120 |
Why?
| | Factor Xa Inhibitors | 1 | 2018 | 194 | 0.120 |
Why?
| | Aged, 80 and over | 7 | 2022 | 8333 | 0.120 |
Why?
| | Disease Models, Animal | 5 | 2017 | 4560 | 0.120 |
Why?
| | Disease-Free Survival | 1 | 2018 | 767 | 0.120 |
Why?
| | Ventricular Function, Left | 2 | 2018 | 542 | 0.120 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2018 | 219 | 0.120 |
Why?
| | Practice Patterns, Physicians' | 1 | 2025 | 1371 | 0.120 |
Why?
| | Anti-Bacterial Agents | 2 | 2019 | 1923 | 0.120 |
Why?
| | Environmental Exposure | 1 | 2021 | 578 | 0.120 |
Why?
| | DNA, Bacterial | 1 | 2017 | 320 | 0.120 |
Why?
| | Receptors, IgG | 2 | 2009 | 77 | 0.120 |
Why?
| | Propensity Score | 2 | 2017 | 377 | 0.120 |
Why?
| | Respiratory Tract Diseases | 1 | 2017 | 175 | 0.120 |
Why?
| | Critical Care | 2 | 2020 | 702 | 0.110 |
Why?
| | Physical Therapy Modalities | 1 | 2019 | 336 | 0.110 |
Why?
| | Antibodies, Monoclonal | 2 | 2014 | 1505 | 0.110 |
Why?
| | Length of Stay | 3 | 2019 | 1349 | 0.110 |
Why?
| | Respiratory Mucosa | 2 | 2009 | 322 | 0.110 |
Why?
| | Emphysema | 3 | 2012 | 100 | 0.110 |
Why?
| | Opioid-Related Disorders | 1 | 2023 | 602 | 0.110 |
Why?
| | CD36 Antigens | 2 | 2006 | 32 | 0.110 |
Why?
| | Biopsy | 1 | 2018 | 1082 | 0.110 |
Why?
| | Gene Expression Regulation | 4 | 2014 | 2597 | 0.100 |
Why?
| | Venous Thromboembolism | 1 | 2018 | 328 | 0.100 |
Why?
| | Hyaluronan Receptors | 2 | 2006 | 104 | 0.100 |
Why?
| | United States | 8 | 2025 | 16098 | 0.100 |
Why?
| | Schistosomiasis mansoni | 1 | 2013 | 25 | 0.100 |
Why?
| | Gastrointestinal Agents | 1 | 2014 | 65 | 0.100 |
Why?
| | Schistosoma mansoni | 1 | 2013 | 41 | 0.100 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2014 | 337 | 0.100 |
Why?
| | Anticoagulants | 1 | 2018 | 748 | 0.100 |
Why?
| | Epithelial Cells | 3 | 2025 | 1131 | 0.090 |
Why?
| | Leukocytes, Mononuclear | 1 | 2016 | 574 | 0.090 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2016 | 248 | 0.090 |
Why?
| | Thymus Gland | 1 | 2014 | 312 | 0.090 |
Why?
| | Biological Transport | 1 | 2014 | 424 | 0.090 |
Why?
| | Echocardiography | 1 | 2016 | 647 | 0.090 |
Why?
| | Interleukin-6 | 3 | 2013 | 776 | 0.090 |
Why?
| | Respiration, Artificial | 3 | 2025 | 713 | 0.090 |
Why?
| | Patient Acceptance of Health Care | 1 | 2019 | 881 | 0.090 |
Why?
| | Mice, Transgenic | 3 | 2013 | 2188 | 0.090 |
Why?
| | Cell Line | 4 | 2012 | 2823 | 0.090 |
Why?
| | Acute Disease | 1 | 2015 | 1036 | 0.090 |
Why?
| | Phosphatidylserines | 2 | 2008 | 62 | 0.090 |
Why?
| | Doxycycline | 1 | 2012 | 62 | 0.090 |
Why?
| | Acetylcysteine | 2 | 2016 | 139 | 0.090 |
Why?
| | Colitis | 1 | 2014 | 280 | 0.080 |
Why?
| | Bronchoalveolar Lavage | 3 | 2017 | 89 | 0.080 |
Why?
| | Pyrroles | 1 | 2012 | 220 | 0.080 |
Why?
| | Glucocorticoids | 1 | 2015 | 531 | 0.080 |
Why?
| | Anti-Inflammatory Agents | 1 | 2014 | 477 | 0.080 |
Why?
| | Multivariate Analysis | 1 | 2014 | 1547 | 0.080 |
Why?
| | Erythrocytes | 2 | 2009 | 748 | 0.080 |
Why?
| | Rural Health Services | 1 | 2011 | 138 | 0.080 |
Why?
| | Membrane Glycoproteins | 3 | 2010 | 499 | 0.080 |
Why?
| | In Vitro Techniques | 2 | 2002 | 1048 | 0.080 |
Why?
| | Adolescent | 5 | 2022 | 22529 | 0.080 |
Why?
| | Health Care Surveys | 1 | 2011 | 536 | 0.080 |
Why?
| | Microbiota | 1 | 2017 | 730 | 0.080 |
Why?
| | Peritonitis | 1 | 2010 | 83 | 0.080 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2930 | 0.080 |
Why?
| | Ceramides | 1 | 2010 | 117 | 0.080 |
Why?
| | Membrane Proteins | 3 | 2006 | 1164 | 0.080 |
Why?
| | Amides | 1 | 2010 | 101 | 0.080 |
Why?
| | Acute Lung Injury | 1 | 2013 | 305 | 0.080 |
Why?
| | Stress Fibers | 1 | 2009 | 18 | 0.080 |
Why?
| | Amiloride | 1 | 2009 | 25 | 0.080 |
Why?
| | Sepsis | 3 | 2020 | 664 | 0.070 |
Why?
| | Thiazolidinediones | 1 | 2010 | 139 | 0.070 |
Why?
| | Phosphorylation | 1 | 2014 | 1707 | 0.070 |
Why?
| | Endotoxemia | 2 | 2001 | 86 | 0.070 |
Why?
| | Alcohol-Related Disorders | 1 | 2010 | 121 | 0.070 |
Why?
| | PPAR gamma | 1 | 2010 | 178 | 0.070 |
Why?
| | Oxygen Consumption | 1 | 2011 | 718 | 0.070 |
Why?
| | Drug Administration Schedule | 1 | 2010 | 782 | 0.070 |
Why?
| | Prevalence | 2 | 2025 | 2865 | 0.070 |
Why?
| | Antigens, Differentiation | 1 | 2008 | 76 | 0.070 |
Why?
| | Statistics, Nonparametric | 1 | 2009 | 428 | 0.070 |
Why?
| | Interleukin-4 | 1 | 2008 | 207 | 0.070 |
Why?
| | Indoles | 1 | 2012 | 507 | 0.070 |
Why?
| | Telephone | 1 | 2009 | 177 | 0.070 |
Why?
| | Gene Expression | 2 | 2010 | 1476 | 0.070 |
Why?
| | Risk Factors | 4 | 2018 | 10885 | 0.070 |
Why?
| | Actins | 1 | 2009 | 425 | 0.060 |
Why?
| | Receptors, Immunologic | 1 | 2008 | 208 | 0.060 |
Why?
| | Blotting, Western | 1 | 2009 | 1179 | 0.060 |
Why?
| | Free Radical Scavengers | 1 | 2006 | 82 | 0.060 |
Why?
| | Hydroxymethylglutaryl CoA Reductases | 1 | 2006 | 13 | 0.060 |
Why?
| | Protein Prenylation | 1 | 2006 | 19 | 0.060 |
Why?
| | Models, Biological | 1 | 2014 | 1764 | 0.060 |
Why?
| | Heart Rate | 3 | 2005 | 855 | 0.060 |
Why?
| | Cross-Sectional Studies | 1 | 2018 | 5904 | 0.060 |
Why?
| | Down-Regulation | 2 | 2025 | 618 | 0.060 |
Why?
| | Mannose-Binding Lectin | 1 | 2006 | 20 | 0.060 |
Why?
| | Pyridines | 1 | 2010 | 609 | 0.060 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2006 | 117 | 0.060 |
Why?
| | Parenteral Nutrition | 1 | 2006 | 102 | 0.060 |
Why?
| | Transcription, Genetic | 2 | 2010 | 1454 | 0.060 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2006 | 174 | 0.060 |
Why?
| | Lysophospholipids | 1 | 2006 | 80 | 0.060 |
Why?
| | Protein Biosynthesis | 1 | 2008 | 452 | 0.060 |
Why?
| | omega-N-Methylarginine | 1 | 2005 | 29 | 0.060 |
Why?
| | Receptors, Complement | 1 | 2006 | 123 | 0.060 |
Why?
| | Health Care Costs | 1 | 2009 | 425 | 0.060 |
Why?
| | Arginine | 1 | 2006 | 264 | 0.060 |
Why?
| | Enhancer of Zeste Homolog 2 Protein | 1 | 2025 | 55 | 0.050 |
Why?
| | Bronchi | 1 | 2006 | 263 | 0.050 |
Why?
| | Regeneration | 1 | 2006 | 197 | 0.050 |
Why?
| | Antigens, CD | 2 | 2006 | 558 | 0.050 |
Why?
| | MAP Kinase Signaling System | 1 | 2006 | 307 | 0.050 |
Why?
| | Patient Satisfaction | 1 | 2009 | 709 | 0.050 |
Why?
| | Single-Blind Method | 3 | 2001 | 318 | 0.050 |
Why?
| | Longitudinal Studies | 1 | 2011 | 2953 | 0.050 |
Why?
| | Blood Pressure | 3 | 2016 | 1779 | 0.050 |
Why?
| | Collagen | 1 | 2006 | 457 | 0.050 |
Why?
| | Monocytes | 1 | 2006 | 539 | 0.050 |
Why?
| | Nitrates | 2 | 2005 | 93 | 0.050 |
Why?
| | HIV Infections | 1 | 2019 | 3193 | 0.050 |
Why?
| | Lung Diseases | 2 | 2009 | 780 | 0.050 |
Why?
| | Analgesia | 1 | 2024 | 106 | 0.050 |
Why?
| | Neoplasms | 1 | 2018 | 2906 | 0.050 |
Why?
| | Databases, Factual | 2 | 2019 | 1490 | 0.050 |
Why?
| | Fibroblasts | 1 | 2008 | 1025 | 0.050 |
Why?
| | Complement Activation | 1 | 2006 | 399 | 0.050 |
Why?
| | Antineoplastic Agents | 1 | 2014 | 2214 | 0.050 |
Why?
| | Patient Readmission | 2 | 2019 | 769 | 0.050 |
Why?
| | Pulmonary Surfactant-Associated Proteins | 1 | 2002 | 9 | 0.050 |
Why?
| | Cathepsin G | 1 | 2002 | 4 | 0.050 |
Why?
| | Proteolipids | 1 | 2002 | 28 | 0.040 |
Why?
| | Macromolecular Substances | 1 | 2002 | 216 | 0.040 |
Why?
| | Cathepsins | 1 | 2002 | 24 | 0.040 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 443 | 0.040 |
Why?
| | Oxidative Stress | 1 | 2009 | 1356 | 0.040 |
Why?
| | Fever | 3 | 2001 | 319 | 0.040 |
Why?
| | Vasopressins | 1 | 2022 | 61 | 0.040 |
Why?
| | Immunotherapy | 1 | 2006 | 666 | 0.040 |
Why?
| | Heart Diseases | 1 | 2005 | 341 | 0.040 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2001 | 75 | 0.040 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2003 | 207 | 0.040 |
Why?
| | Colorado | 1 | 2011 | 4553 | 0.040 |
Why?
| | Jumonji Domain-Containing Histone Demethylases | 1 | 2002 | 64 | 0.040 |
Why?
| | Norepinephrine | 1 | 2022 | 201 | 0.040 |
Why?
| | Pulmonary Surfactants | 1 | 2002 | 105 | 0.040 |
Why?
| | Serine Endopeptidases | 1 | 2002 | 128 | 0.040 |
Why?
| | Vasoconstrictor Agents | 1 | 2022 | 150 | 0.040 |
Why?
| | Carbon Dioxide | 2 | 2001 | 227 | 0.040 |
Why?
| | Critical Care Outcomes | 1 | 2020 | 11 | 0.040 |
Why?
| | Status Asthmaticus | 1 | 2020 | 13 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2009 | 3542 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 2004 | 1368 | 0.040 |
Why?
| | Cell Differentiation | 1 | 2008 | 2046 | 0.040 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2001 | 345 | 0.040 |
Why?
| | Cell Communication | 1 | 2002 | 328 | 0.040 |
Why?
| | Rural Population | 1 | 2025 | 659 | 0.040 |
Why?
| | Vascular Resistance | 2 | 2016 | 370 | 0.040 |
Why?
| | Sputum | 1 | 2002 | 302 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2025 | 679 | 0.040 |
Why?
| | Chronic Disease | 1 | 2006 | 1808 | 0.040 |
Why?
| | Glycoproteins | 1 | 2002 | 354 | 0.040 |
Why?
| | Young Adult | 4 | 2019 | 14218 | 0.040 |
Why?
| | NADPH Oxidase 2 | 2 | 2010 | 32 | 0.040 |
Why?
| | Autoimmunity | 1 | 2006 | 933 | 0.040 |
Why?
| | Dyspnea | 1 | 2001 | 250 | 0.040 |
Why?
| | Cross-Over Studies | 2 | 1999 | 608 | 0.040 |
Why?
| | Cyclic GMP | 1 | 1999 | 90 | 0.040 |
Why?
| | Macrophage Inflammatory Proteins | 1 | 1999 | 11 | 0.040 |
Why?
| | NADPH Oxidases | 2 | 2010 | 122 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2017 | 3623 | 0.040 |
Why?
| | Mice, Inbred BALB C | 2 | 2013 | 1261 | 0.040 |
Why?
| | Endothelium, Vascular | 2 | 2003 | 956 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 1999 | 428 | 0.030 |
Why?
| | Hospitals, Rural | 1 | 2018 | 49 | 0.030 |
Why?
| | Hospital Charges | 1 | 2017 | 46 | 0.030 |
Why?
| | Hospitals, Urban | 1 | 2018 | 142 | 0.030 |
Why?
| | Comparative Effectiveness Research | 1 | 2018 | 168 | 0.030 |
Why?
| | Cellular Reprogramming | 1 | 2018 | 98 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2004 | 1747 | 0.030 |
Why?
| | Muscular Diseases | 1 | 2017 | 108 | 0.030 |
Why?
| | Bayes Theorem | 1 | 2019 | 420 | 0.030 |
Why?
| | Time Factors | 2 | 2018 | 7123 | 0.030 |
Why?
| | Thrombocytopenia | 1 | 2018 | 204 | 0.030 |
Why?
| | Protein Binding | 1 | 2002 | 2238 | 0.030 |
Why?
| | Cytokines | 3 | 2013 | 2067 | 0.030 |
Why?
| | Teichoic Acids | 1 | 2016 | 18 | 0.030 |
Why?
| | Biomarkers | 2 | 2019 | 4295 | 0.030 |
Why?
| | Surveys and Questionnaires | 1 | 2009 | 6066 | 0.030 |
Why?
| | Receptors, Interleukin-1 | 1 | 1996 | 211 | 0.030 |
Why?
| | Comorbidity | 1 | 2020 | 1661 | 0.030 |
Why?
| | Systole | 1 | 2016 | 181 | 0.030 |
Why?
| | Acute Kidney Injury | 2 | 2014 | 875 | 0.030 |
Why?
| | Risk | 1 | 2018 | 919 | 0.030 |
Why?
| | Capillary Permeability | 1 | 2016 | 132 | 0.030 |
Why?
| | Lung Diseases, Interstitial | 1 | 2002 | 664 | 0.030 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 2 | 2009 | 41 | 0.030 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2017 | 507 | 0.030 |
Why?
| | Cell Membrane | 2 | 2010 | 707 | 0.030 |
Why?
| | Toll-Like Receptor 2 | 1 | 2016 | 125 | 0.030 |
Why?
| | Transcription Factors | 1 | 2003 | 1734 | 0.030 |
Why?
| | Amino Acid Oxidoreductases | 1 | 1994 | 19 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 777 | 0.030 |
Why?
| | Dogs | 2 | 2006 | 458 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 2016 | 571 | 0.030 |
Why?
| | Immunologic Factors | 1 | 1996 | 260 | 0.030 |
Why?
| | Ipilimumab | 1 | 2014 | 40 | 0.030 |
Why?
| | ROC Curve | 1 | 2016 | 617 | 0.030 |
Why?
| | Flow Cytometry | 2 | 2009 | 1162 | 0.030 |
Why?
| | Recombinant Fusion Proteins | 1 | 1996 | 666 | 0.020 |
Why?
| | Toll-Like Receptor 4 | 1 | 2016 | 276 | 0.020 |
Why?
| | Infliximab | 1 | 2014 | 111 | 0.020 |
Why?
| | Mice, 129 Strain | 1 | 2013 | 84 | 0.020 |
Why?
| | Phylogeny | 1 | 2017 | 917 | 0.020 |
Why?
| | Blood Urea Nitrogen | 1 | 2013 | 53 | 0.020 |
Why?
| | Hemorrhage | 1 | 2018 | 822 | 0.020 |
Why?
| | Hypotension | 1 | 2014 | 127 | 0.020 |
Why?
| | Diarrhea | 1 | 2014 | 193 | 0.020 |
Why?
| | Logistic Models | 1 | 2017 | 2134 | 0.020 |
Why?
| | Transfection | 2 | 2006 | 926 | 0.020 |
Why?
| | Endothelial Cells | 2 | 2010 | 874 | 0.020 |
Why?
| | Antioxidants | 1 | 2016 | 550 | 0.020 |
Why?
| | Vasoconstriction | 1 | 2013 | 216 | 0.020 |
Why?
| | Cardiac Catheterization | 1 | 2016 | 558 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 2 | 2010 | 2524 | 0.020 |
Why?
| | Pulmonary Circulation | 1 | 2013 | 430 | 0.020 |
Why?
| | Trachea | 1 | 2013 | 258 | 0.020 |
Why?
| | Creatinine | 1 | 2013 | 515 | 0.020 |
Why?
| | Healthcare Disparities | 1 | 2018 | 735 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 1999 | 3413 | 0.020 |
Why?
| | Ceramidases | 1 | 2010 | 4 | 0.020 |
Why?
| | Zymosan | 1 | 2010 | 39 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2013 | 1300 | 0.020 |
Why?
| | Nitric Oxide Synthase | 2 | 2005 | 234 | 0.020 |
Why?
| | Lung Compliance | 1 | 2009 | 42 | 0.020 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2009 | 80 | 0.020 |
Why?
| | RNA, Messenger | 2 | 2010 | 2803 | 0.020 |
Why?
| | Gene Deletion | 1 | 2010 | 391 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 977 | 0.020 |
Why?
| | Rats | 2 | 2010 | 5584 | 0.020 |
Why?
| | 3T3 Cells | 1 | 2008 | 156 | 0.020 |
Why?
| | Capillaries | 1 | 2009 | 125 | 0.020 |
Why?
| | Binding, Competitive | 1 | 2008 | 185 | 0.020 |
Why?
| | Pulmonary Emphysema | 1 | 2010 | 277 | 0.020 |
Why?
| | Leukocytes | 1 | 2009 | 296 | 0.020 |
Why?
| | Interleukin-10 | 1 | 2009 | 309 | 0.020 |
Why?
| | Melanoma | 1 | 2014 | 759 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 848 | 0.020 |
Why?
| | ATP Binding Cassette Transporter 1 | 1 | 2006 | 13 | 0.020 |
Why?
| | Receptors, LDL | 1 | 2006 | 53 | 0.020 |
Why?
| | Gene Targeting | 1 | 2006 | 81 | 0.020 |
Why?
| | Syk Kinase | 1 | 2006 | 19 | 0.010 |
Why?
| | Fetal Distress | 1 | 2006 | 14 | 0.010 |
Why?
| | Random Allocation | 1 | 2006 | 365 | 0.010 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2006 | 109 | 0.010 |
Why?
| | Immunity | 1 | 2006 | 140 | 0.010 |
Why?
| | Nitrites | 1 | 2005 | 87 | 0.010 |
Why?
| | Hyperoxia | 1 | 2006 | 96 | 0.010 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 2006 | 107 | 0.010 |
Why?
| | RNA Interference | 1 | 2006 | 475 | 0.010 |
Why?
| | Tumor Suppressor Proteins | 1 | 2006 | 321 | 0.010 |
Why?
| | Caenorhabditis elegans Proteins | 1 | 2006 | 207 | 0.010 |
Why?
| | Drug Therapy, Combination | 1 | 2006 | 1044 | 0.010 |
Why?
| | Child | 2 | 2021 | 22707 | 0.010 |
Why?
| | Genes, Dominant | 1 | 2003 | 100 | 0.010 |
Why?
| | Survival Analysis | 1 | 2006 | 1374 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 2006 | 1327 | 0.010 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2006 | 431 | 0.010 |
Why?
| | Homeostasis | 1 | 2006 | 642 | 0.010 |
Why?
| | Chimera | 1 | 2002 | 61 | 0.010 |
Why?
| | Oxidation-Reduction | 1 | 2006 | 1067 | 0.010 |
Why?
| | Neutrophil Infiltration | 1 | 2002 | 104 | 0.010 |
Why?
| | Neovascularization, Physiologic | 1 | 2003 | 192 | 0.010 |
Why?
| | Hypoxia | 1 | 2009 | 1199 | 0.010 |
Why?
| | Interleukin-1 | 2 | 1996 | 961 | 0.010 |
Why?
| | Stroke Volume | 1 | 2005 | 654 | 0.010 |
Why?
| | Double-Blind Method | 1 | 2006 | 2062 | 0.010 |
Why?
| | Cell Count | 1 | 2002 | 319 | 0.010 |
Why?
| | Respiratory Muscles | 1 | 2001 | 37 | 0.010 |
Why?
| | Cell Division | 1 | 2003 | 756 | 0.010 |
Why?
| | Enzyme Inhibitors | 1 | 2005 | 820 | 0.010 |
Why?
| | Blood Gas Analysis | 1 | 2001 | 81 | 0.010 |
Why?
| | Chemokines | 1 | 2002 | 217 | 0.010 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2002 | 177 | 0.010 |
Why?
| | Stress, Mechanical | 1 | 2003 | 494 | 0.010 |
Why?
| | Bone Marrow Transplantation | 1 | 2002 | 298 | 0.010 |
Why?
| | Bleomycin | 1 | 2002 | 255 | 0.010 |
Why?
| | Hyaluronic Acid | 1 | 2002 | 226 | 0.010 |
Why?
| | Proteins | 1 | 2006 | 1023 | 0.010 |
Why?
| | Chemokine CCL4 | 1 | 1999 | 31 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2003 | 1716 | 0.010 |
Why?
| | Chemokine CCL3 | 1 | 1999 | 26 | 0.010 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 1999 | 82 | 0.010 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 1999 | 162 | 0.010 |
Why?
| | Shivering | 1 | 1996 | 5 | 0.010 |
Why?
| | Acute-Phase Reaction | 1 | 1996 | 37 | 0.010 |
Why?
| | Blood Cell Count | 1 | 1996 | 55 | 0.010 |
Why?
| | Toxemia | 1 | 1996 | 4 | 0.010 |
Why?
| | Lactoferrin | 1 | 1996 | 36 | 0.010 |
Why?
| | Sialoglycoproteins | 1 | 1996 | 157 | 0.010 |
Why?
| | Solubility | 1 | 1996 | 240 | 0.010 |
Why?
| | Kinetics | 1 | 1999 | 1567 | 0.010 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 1996 | 253 | 0.010 |
Why?
| | Calmodulin | 1 | 1994 | 70 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2006 | 6447 | 0.010 |
Why?
| | Cytosol | 1 | 1994 | 213 | 0.010 |
Why?
| | Phenotype | 1 | 2002 | 3155 | 0.010 |
Why?
| | Electrocardiography | 1 | 1996 | 665 | 0.010 |
Why?
| | Peptide Fragments | 1 | 1996 | 693 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 2006 | 2664 | 0.010 |
Why?
| | Cattle | 1 | 1994 | 946 | 0.010 |
Why?
| | Hemodynamics | 1 | 1996 | 1118 | 0.010 |
Why?
| | Interferon-gamma | 1 | 1994 | 784 | 0.010 |
Why?
| | Sulfonamides | 1 | 1994 | 583 | 0.000 |
Why?
| | Prospective Studies | 1 | 1996 | 8057 | 0.000 |
Why?
|
|
Vandivier's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|